SCHEMBL860870

SCHEMBL860870

CC(NC(=O)CC(=O)Nc1ccc(C(=N)N)cc1)c1ccc(OCC2CCOC2)c(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
F7 P08709 17/20 0.52
F2 P00734 11/20 0.52
P2RX4 Q99571 1/20 0.42
F10 P00742 1/20 0.40
XDH P47989 1/20 0.40
SCN8A Q9UQD0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL860781 0.86 F7 (0.50) F7F2F10
SCHEMBL860322 0.86 F2 (0.56) F7F2F10
SCHEMBL860354 0.86 F7 (0.49) F7F2F10
SCHEMBL8107112 0.85 F7 (0.49) F7F2F10
SCHEMBL860775 0.83 F7 (0.53) F7F2P2RX4F10
SCHEMBL860316 0.82 F7 (0.51) F7F2F10
SCHEMBL860352 0.82 F7 (0.52) F7F2F10
SCHEMBL842037 0.81 F7 (0.50) F7F2F10
SCHEMBL841073 0.81 F7 (0.50) F7F2F10
SCHEMBL860311 0.81 F7 (0.49) F7F2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143242-B2 Malonamide derivatives with antithrombotic activity SANOFI-AVENTIS (FR) 2012-03-27 US disclosed
US-8143242-B2 Malonamide derivatives with antithrombotic activity SANOFI-AVENTIS (FR) 2012-03-27 US disclosed
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2010-09-30 US disclosed
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY SANOFI-AVENTIS (FR) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249101-A1 MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY F7, F9, TFPI F7 1/4885F2 23/4885P2RX4 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.